Psilocybin for Aging

(LONG-LIFE Trial)

This trial explores whether psilocybin, a compound in certain mushrooms, can affect aspects of aging such as mental sharpness and life satisfaction in older adults. Participants will receive one, two, or three doses of psilocybin, or join a group that does not receive it immediately. Researchers aim to determine how different doses impact aging markers and cognitive function over a year. The trial seeks medically stable individuals aged 60-80 interested in enhancing their cognitive health and sense of purpose. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this innovative treatment.

Research has shown that psilocybin can be safe and well-tolerated in older adults. Some studies have found that psilocybin might raise blood pressure and heart rate, but this usually concerns only those with heart problems. Safety data indicate that older adults in psilocybin-assisted therapy generally handled it well.

One study showed that the Food and Drug Administration (FDA) considers psilocybin to have a good safety profile, meaning it usually has only minor side effects. However, monitoring for any possible reactions remains important, especially in older adults.

Researchers are excited about psilocybin for aging because it offers a novel approach compared to traditional treatments like antioxidants or hormone replacement therapies. Unlike these treatments, psilocybin, a compound found in certain mushrooms, works by targeting the brain's serotonin receptors, potentially enhancing mood and cognitive function in a way that standard treatments do not. Additionally, psilocybin's effects can be felt relatively quickly, often within hours, and may offer lasting benefits after just one to three doses, which is a promising contrast to the longer timelines required by other aging-related therapies.

This trial will explore the effects of psilocybin on aging, with participants receiving different dosing regimens. Research suggests that psilocybin might positively affect aging. Studies have shown that psilocybin can help cells live longer and repair their DNA, which are crucial for slowing down aging. In experiments, psilocybin also reduced cellular damage caused by oxidative stress over time. Animal studies found that psilocybin treatment increased lifespan, even when started later in life. Additionally, evidence indicates that psilocybin might support brain health by promoting changes that counteract typical aging effects. These findings suggest that psilocybin could potentially help older adults by addressing several key aspects of aging.³⁴⁶⁷⁸